High Density Lipoprotein Nanoparticles for siRNA Delivery

用于 siRNA 递送的高密度脂蛋白纳米颗粒

• 批准号: 8549175
• 负责人: Colby Shad Thaxton
• 金额: $ 30.14万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-21 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8549175
• 关键词: Address; Affinity; Anabolism; Androgen Antagonists; Androgen Receptor; Androgens; Antisense Oligonucleotides; Binding; Biocompatible; Biocompatible Materials; Biological; Biomimetics; Bypass; Caliber; Cell Culture Techniques; Cells; Chemical Engineering; Chemistry; Cholesterol; Clinical; Cytoplasm; Early Endosome; Epithelial Cells; Exocytosis; Failure; Gene Expression; Gene Expression Regulation; Gene Targeting; Gold; Growth; Health; Hepatocyte; High Density Lipoprotein Cholesterol; High Density Lipoproteins; In Situ; In Vitro; Kinetics; Lipoprotein Receptor; Lipoproteins; Low-Density Lipoproteins; Lysosomes; Malignant Neoplasms; Malignant neoplasm of prostate; Measures; Mediator of activation protein; Methods; MicroRNAs; Modality; Modeling; Mus; Nanoconjugate; Nanostructures; Nuclear; Nucleic Acids; Pathway interactions; Patients; Pharmacology; Pre-Clinical Model; Production; Property; Prostate; Quality of life; Recombinants; Resistance; Serum; Shapes; Site; Small Interfering RNA; Solutions; Specificity; Surface; Technology; Testing; Testosterone; Therapeutic; Tissues; Toxic effect; Treatment Efficacy; Vascular Endothelial Growth Factor Receptor-2; aqueous; base; cancer cell; cancer therapy; combat; deprivation; effective therapy; flexibility; gene therapy; high density lipoprotein receptor; in vivo; innovation; macrophage; migration; mortality; multidisciplinary; nanoparticle; neoplastic cell; novel; novel strategies; prostate cancer cell; prototype; receptor; receptor expression; research study; response; scaffold; scavenger receptor; self assembly; small molecule; success; targeted delivery; tumor; tumor progression; uptake

DESCRIPTION (provided by applicant): We aim to develop a targeted nanoparticle-based cancer therapy. We chose advanced prostate cancer (PCa) because androgen deprivation therapy (ADT), the only effective therapeutic option, fails after a relatively brief initial respone. Because of its high mortality rate, and significant impact on patient quality of life, novel treatment modalities for advanced PCa are highly important and much needed. The failure of anti-androgens is due, at least in part, to autonomous local testosterone production by PCa tumor cells. As a result, advanced PCa develops a unique requirement for cholesterol, which is a substrate for androgen biosynthesis. Cholesterol, insoluble in aqueous solution, is internalized via lipoproteins, specifically high density lipoproteins (HDL) in PCa. HDL and cholesterol uptake occur through the HDL uptake receptor, scavenger receptor B-1 (SR-B1), which is up-regulated in advanced PCa. We will employ the increased SR-B1 expression for PCa targeting with nanoconjugates to deliver gene targeted siRNA. We hypothesize that efficient systemic delivery of nucleic acid cargo can be facilitated by the robust and directed fabrication of biomimetic spherical HDL nanoparticles using a novel approach pioneered by our group. Recently, our group utilized a gold nanoparticle scaffold (AuNP) to generate biomimetic HDLs that recapitulate the size, shape, surface chemistry, and cholesterol binding properties of mature spherical HDLs. The resulting nanoparticles (HDL AuNPs) adsorb nucleic acids with high affinity. Initial in vitro and in vivo experiments show that these unique biomaterials are non-toxic, accumulate in the tissues that normally bind HDL, and function to regulate target gene expression. We propose to characterize and optimize the HDL AuNP conjugates loaded with siRNA and to test their properties in vitro and in preclinical model of prostate cancer. We expect that HDL AuNPs carrying siRNA will accumulate in the sites of SR-B1 expression, including in experimental PCa where SR-B1 is over-expressed, and efficiently deliver siRNA to PCa cells. Thus delivered, siRNA will block the expression of target gene(s). As a model target we chose the androgen receptor, a critical mediator of advanced prostate cancer. Project success will result in an effective and targeted siRNA therapy for advanced prostate cancer.

描述（由申请人提供）：我们的目标是开发一种基于纳米颗粒的靶向癌症治疗方法。我们选择晚期前列腺癌（PCa），因为雄激素剥夺疗法（ADT）是唯一有效的治疗选择，在相对短暂的初始反应后失败。由于其高死亡率和对患者生活质量的重大影响，晚期前列腺癌的新治疗方式非常重要和迫切需要。抗雄激素的失效，至少部分是由于前列腺癌肿瘤细胞自主产生的局部睾酮。因此，晚期前列腺癌对雄激素生物合成的底物胆固醇产生了独特的需求。胆固醇不溶于水溶液，通过脂蛋白，特别是PCa中的高密度脂蛋白（HDL）内化。HDL和胆固醇摄取通过HDL摄取受体，清道夫受体B-1 （SR-B1）发生，在晚期PCa中上调。我们将利用增加的SR-B1表达，用纳米偶联物靶向PCa来传递基因靶向siRNA。我们假设，通过使用我们团队首创的一种新方法，稳健和定向制造仿生球形HDL纳米颗粒，可以促进核酸货物的有效全身递送。最近，我们的团队利用金纳米颗粒支架（AuNP）来生成仿生高密度脂蛋白，再现了成熟球形高密度脂蛋白的大小、形状、表面化学和胆固醇结合特性。所得纳米颗粒（HDL - AuNPs）对核酸具有高亲和力。初步的体外和体内实验表明，这些独特的生物材料无毒，可在正常结合HDL的组织中积累，并具有调节靶基因表达的功能。我们建议对负载siRNA的HDL - AuNP偶联物进行表征和优化，并在体外和前列腺癌临床前模型中测试其性能。我们预计，携带siRNA的HDL - AuNPs将在SR-B1表达位点积聚，包括在SR-B1过表达的实验性PCa中，并有效地将siRNA传递到PCa细胞。因此，siRNA将阻断靶基因的表达。我们选择雄激素受体作为模型靶点，雄激素受体是晚期前列腺癌的关键介质。项目的成功将为晚期前列腺癌提供有效的靶向siRNA治疗。